Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.43 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | DGKA | P23743 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.42 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.42 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27425959 | 1.00 | DNM1 (0.43) | DNM1NAAADGKAHTR2CPRSS1 | |
| SCHEMBL27425953 | 1.00 | DNM1 (0.43) | DNM1NAAADGKAHTR2CPRSS1 | |
| SCHEMBL27425962 | 1.00 | DNM1 (0.43) | DNM1NAAADGKAHTR2CPRSS1 | |
| SCHEMBL27425957 | 1.00 | DNM1 (0.43) | DNM1NAAADGKAHTR2CPRSS1 | |
| SCHEMBL27425949 | 0.86 | LPAR1 (0.44) | — | |
| SCHEMBL27425944 | 0.86 | LPAR1 (0.44) | — | |
| SCHEMBL27425947 | 0.86 | LPAR1 (0.44) | — | |
| SCHEMBL27425945 | 0.86 | LPAR1 (0.44) | — | |
| SCHEMBL5078244 | 0.83 | DGKA (0.53) | DNM1NAAADGKAHTR2CPRSS1 | |
| SCHEMBL17909237 | 0.82 | DGKA (0.59) | DNM1NAAADGKAHTR2CPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024484-B2 | Lipid formulations for gene editing | VERVE THERAPEUTICS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024484-B2 | Lipid formulations for gene editing | LIPA, LIPC, ABHD16A | DNM1 483/4885NAAA 1174/4885DGKA 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.